Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by wofatson Sep 29, 2021 3:47pm
124 Views
Post# 33938312

RE:RE:RE:Biogen's Aduhelm ...

RE:RE:RE:Biogen's Aduhelm ...

Aduhelm’s approval was so controversial earlier this summer that three members of the FDA’s advisory committee resigned when their near-unanimous decision not to recommend the drug was ignored. The price tag of $56,000 has also been heavily criticised.

It has been reported that the roll-out has been far slower than expected with only around 100 patients receiving the infusion in total. Many clinics have announced that they would not be using Aduhelm, including the Cleveland Clinic and Mount Sinai, with one Washington-DC-based clinic taking the worrying step of banning Biogen reps from the premises.

More attention is also being paid to Aduhelm’s side effects, specially ARIA – amyloid-related imaging abnormalities. The most common form is ARIA-E, a type of cerebral oedema that is associated with headache, confusion, nausea and gait disturbances, among other symptoms.

<< Previous
Bullboard Posts
Next >>